1. Home
  2. Labeler Index
  3. Nucare Pharmaceuticals,inc.
  4. 68071-4508
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Levetiracetam NDC 68071-4508 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

PDP - 68071 4508 6 Z13

PDP - 68071 4508 6 Z13

This is a description of a medication called Levetiracetam 500mg. It is a pink colored tablet that is scored and oblong-shaped. Each bottle contains 60 tablets with Lot # and Expiration Date. There are warnings on the label to keep it out of reach of children, and it can only be obtained with a prescription. The medication is to be stored at controlled temperature between 59-86°F.*

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 02

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 02

This is a formula to estimate the glomerular filtration rate (GFR) in adults. It requires the values of age, weight, and serum creatinine. If the patient is female, the result must be multiplied by 0.85. However, there is not enough information to determine the actual GFR value.*

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 03

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 03

Levetiracetam Structural Formula - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 04

Levetiracetam Structural Formula - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 04

Figure 1: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 1 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 05

Figure 1: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 1 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 05

The text describes a figure (Figure 1) showing the responder rate (>50% reduction from baseline) in a study (Study 1). The figure shows a graph with percentages on the Y-axis ranging from 0% to 45%, while the X-axis shows three categories. The categories are Placebo (representing 95 participants), Levetiracetam 1000 mg/day (representing 37 participants), and Levetiracetam 3000 mg/day (representing 101 participants). The figure shows that the responder rate was statistically significant versus placebo for the Levetiracetam 3000 mg/day group.*

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 06

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 06

The text represents a figure, specifically "Responder Rate" showing the percentage of people with a more than 50% reduction from baseline in "Study 2, Period A" for the placebo group and two groups receiving different doses of Levetiracetam. It notes that one of the Levetiracetam groups had a statistically significant difference compared to placebo.*

Figure 3: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 07

Figure 3: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 07

The text describes a figure indicating the responder rate (with >50% reduction from baseline) in Study 3, where two treatment groups (placebo and Levetiracetam 3000mg/day) were compared. The figure shows that the responder rate was statistically significant in the Levetiracetam group compared to the placebo group.*

Figure 4: Responder Rate (greater than or equal to 50% Reduction from Baseline) - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 08

Figure 4: Responder Rate (greater than or equal to 50% Reduction from Baseline) - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 08

figure 5 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 09

figure 5 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 09

ot-available*

Figure 6: Responder Rate (greater than or equal to 50% Reduction from Baseline) in PGTC Seizure Frequency per Week - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 10

Figure 6: Responder Rate (greater than or equal to 50% Reduction from Baseline) in PGTC Seizure Frequency per Week - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 10

The text describes a figure, labeled as Figure 6, that shows the responder rate in PGTC seizure frequency per week in Study 7. The responder rate is defined as a reduction of 50% from the baseline frequency. The graph shows the percentage of responders on the vertical axis and the treatment groups on the horizontal axis. There were two treatment groups shown, Placebo and Levetiracetam, with 84 patients in the Placebo group. The Levetiracetam group had a statistically significant difference compared to the Placebo group. The percentage of responders in the Levetiracetam group was 72.2% and the percentage of responders in the Placebo group was 45.2%.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.